Insider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells $455,585.10 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 4,090 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Down 1.8%

Shares of NASDAQ:MNPR opened at $111.89 on Friday. Monopar Therapeutics Inc. has a fifty-two week low of $32.77 and a fifty-two week high of $124.82. The firm has a 50-day simple moving average of $106.44 and a 200 day simple moving average of $75.00. The company has a market cap of $750.78 million, a PE ratio of -51.56 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -2.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MNPR. Barclays restated an “overweight” rating and set a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.67.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in shares of Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after acquiring an additional 30,042 shares during the period. RA Capital Management L.P. increased its stake in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after acquiring an additional 156,000 shares during the period. Siren L.L.C. increased its stake in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC raised its holdings in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in Monopar Therapeutics during the third quarter worth approximately $18,904,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.